Divi's Laboratories fared well on the revenue front in Q1FY23, but Ebitda margin was at a nine-quarter low due to cost inflation
After a good run in financial year 2022, Divi’s Laboratories Ltd has two main problems to grapple with. One, the benefits it saw from the pandemic are set to wane with the expected drop in the sales of covid antiviral drug, molnupiravir, revenues of which are included in the company’s custom synthesis (CS) business. Divi’s manufactures generic active pharmaceutical ingredients (APIs) and is also present in the CS segment.
Recommended For You
Select your Category
Internet Not Available
Wait for it…
Log in to our website to save your bookmarks. It'll just take a moment.